Edwin J. Ostrin

Associate Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Supplementary Table S7: Lung cancers characteristics diagnosed during the active phase of the LEAP study based on the selection method for inclusion criteria: NLST criteria vs broadened criteria (≥ 20 pack-years, ≥ 50 years old, one additional lung cancer risk factor)

Year:

2026

Background: Blood-based biomarkers could improve the effectiveness of lung cancer screening (LCS) with low-dose CT (LDCT) through more accurate lung cancer risk stratification and nodule malignancy risk assessment. The Lung Cancer, Early Detection, Assessment of Risk, and Prevention (LEAP) study aims to establish a reference set to validate promising cancer biomarkers in the context of LCS. Methods: This prospective international cohort study (United States, France, and Spain) enrolled individuals with elevated risk of developing lung cancer based on National Comprehensive Cancer Network Guidelines into an LCS program. Participants underwent three annual rounds of LDCT-LCS, with blood specimens collected at each time point. Questionnaires and medical chart reviews were utilized to determine participants’ cancers status. Results: Between 2014 and 2019, 2,841 participants were enrolled who underwent LDCT: 2,841 at baseline, 2,097 at year 1 (74%), and 1,779 at year 2 (63%). Rates at baseline, year 1, and year 2 were positive scans (13%, 7.5%, and 7.5%, respectively), false positives (12%, 6.8%, and 6.9%, respectively), and screen-detected lung cancer (0.9%, 0.9%, and 0.7%, respectively). After 5 years of follow-up, 74 lung cancer cases were detected: 55% stage I, 11% stage II, 16% stage III, and 12% stage IV. The LEAP biobank collected 6,586 blood specimens, including 126 (lung) and 201 (other) prediagnostic samples within 5 years of diagnosis. Conclusions: The LEAP cohort provides a resource with a longitudinal database of participant data, LDCT imaging, and matched blood specimens for biomarker validation, aiming to address unmet clinical needs in LCS. Impact: LEAP provides longitudinal biospecimens linked with clinical follow-up and LDCT imaging for biomarker validation in the context of imaging findings and lung cancer diagnosis.

Year:

2026

Supplementary Table S6: Analysis of LDCT screening results in the LEAP cohort based on the selection method for inclusion criteria: NLST criteria vs broadened criteria (≥ 20 pack-years, ≥ 50 years old, one additional lung cancer risk factor)

Year:

2026

This study aimed to assess a four-marker protein panel (4MP)’s performance, including the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19, for predicting lung cancer in a cohort enriched with never- and ever-smokers. Blinded pre-diagnostic plasma samples collected within 2 years prior to a lung cancer diagnosis from 25 cases and 100 sex-, age-, and smoking-matched controls were obtained from the Physicians’ Health Study (PHS). The 4MP yielded AUC performance estimates of 0.76 (95% CI: 0.61–0.92) and 0.69 (95% CI: 0.56–0.82) for predicting lung cancer within one year and within two years of diagnosis, respectively. When stratifying into ever-smokers and never-smokers, the 4MP had respective AUCs of 0.77 (95% CI: 0.63–0.92) and 0.72 (95% CI: 0.17–1.00) for a 1-year risk of lung cancer. The AUCs of the 4MP for predicting metastatic lung cancer within one year and two years of the blood draw were 0.95 (95% CI: 0.87–1.00) and 0.78 (95% CI: 0.62–0.94), respectively. Our findings indicate that a blood-based biomarker panel may be useful in identifying ever- and never-smokers at high risk of a diagnosis of lung cancer within one-to-two years.

Year:

2024

Studying lung adenocarcinoma (LUAD) early carcinogenesis is challenging, primarily due to the lack of LUAD precursors specimens. We amassed multi-omics data from 213 LUAD and LUAD precursors to identify molecular features underlying LUAD precancer evolution. We observed progressively increasing mutations, chromosomal aberrations, whole genome doubling and genomic instability from precancer to invasive LUAD, indicating aggravating chromosomal instability (CIN). Telomere shortening, a crucial genomic alteration linked to CIN, emerged at precancer stage. Moreover, later-stage lesions demonstrated increasing cancer stemness and decreasing alveolar identity, suggesting epithelial de-differentiation during early LUAD carcinogenesis. The innate immune cells progressively diminished from precancer to invasive LUAD, concomitant with a gradual recruitment of adaptive immune cells (except CD8+ and gamma-delta T cells that decreased in later stages) and upregulation of numerous immune checkpoints, suggesting LUAD precancer evolution is associated with a shift from innate to adaptive immune response and immune evasion mediated by various mechanisms.

Year:

2024

PURPOSE To investigate the utility of integrating a panel of circulating protein biomarkers in combination with a risk model on the basis of subject characteristics to identify individuals at high risk of harboring a lethal lung cancer. METHODS Data from an established logistic regression model that combines four-marker protein panel (4MP) together with the Prostate, Lung, Colorectal, and Ovarian (PLCO) risk model (PLCO m2012 ) assayed in prediagnostic sera from 552 lung cancer cases and 2,193 noncases from the PLCO cohort were used in this study. Of the 552 lung cancer cases, 387 (70%) died of lung cancer. Cumulative incidence of lung cancer death and subdistributional and cause-specific hazard ratios (HRs) were calculated on the basis of 4MP + PLCO m2012 risk scores at a predefined 1.0% and 1.7% 6-year risk thresholds, which correspond to the current and former US Preventive Services Task Force screening criteria, respectively. RESULTS When considering cases diagnosed within 1 year of blood draw and all noncases, the area under receiver operation characteristics curve estimate of the 4MP + PLCO m2012 model for risk prediction of lung cancer death was 0.88 (95% CI, 0.86 to 0.90). The cumulative incidence of lung cancer death was statistically significantly higher in individuals with 4MP + PLCO m2012 scores above the 1.0% 6-year risk threshold (modified χ 2 , 166.27; P < .0001). Corresponding subdistributional and lung cancer death–specific HRs for test-positive cases were 9.88 (95% CI, 6.44 to 15.18) and 10.65 (95% CI, 6.93 to 16.37), respectively. CONCLUSION The blood-based biomarker panel in combination with PLCO m2012 identifies individuals at high risk of a lethal lung cancer.

Year:

2023

Collaborators (20)

Xiuning Le

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Gerber

Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences

University of Texas Southwestern Medical Center

UNITED STATES
View details

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mark Davis

Howard Hughes Medical Institute

UNITED STATES
View details

Christos Chouaid

Centre Hospitalier Intercommunal de Créteil

FRANCE
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

John V. Heymach

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Chao Cheng

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Natalie Vokes

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mara B. Antonoff

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kim‐Anh Do

-

UNITED STATES
View details

Alexandre Reuben

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Simon Heeke

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Humam Kadara

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jia Wu

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details